

To
Board of Directors of
M/S GENLINK PHARMA SOLUTIONS PRIVATE LIMITED,
(Formerly known as Genlink Pharma Investment Private Limited)
Mumbai

Dear Sir,

Re: **Auditor's Report on Yearly Financial Results as on 31st March, 2017 of M/s GENLINK PHARMA SOLUTIONS PRIVATE LIMITED, (formerly known as GENLINK INVESTMENT PRIVATE LIMITED) pursuant to the Regulation 52 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.**

Introduction

We have audited the Yearly Financial results of **M/s GENLINK PHARMA SOLUTIONS PRIVATE LIMITED, (formerly known as GENLINK INVESTMENT PRIVATE LIMITED)** for the year to date results for the period 01st April, 2016 to 31st March, 2017, attached herewith, being submitted by the company pursuant to the requirement of Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These yearly financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the Company's Management and have been approved by the Board of Directors. Our responsibility is to express an opinion on these financial statements based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25 / Ind AS 34), prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued there under; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

Scope of Review

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance as to whether the financial statements are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by Management. We believe that our audit provides a reasonable basis for our opinion.

Conclusion

In our opinion and to the best of our information and according to the explanations given to us these yearly financial results to date results:

- (i) are presented in accordance with the requirements of Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (ii) give a true and fair view of the net loss and other financial information for the year to date results for the period from 01st April, 2016 to 31st March, 2017

**For SHANKARLAL JAIN & ASSOCIATES LLP,
CHARTERED ACCOUNTANTS
FIRM REG. NO.:109901W/W100082**

Sd/-

PLACE: MUMBAI

DATE: 23/01/2018

**SATISH JAIN
PARTNER
MEMBERSHIP NO. 48874**

Genlink Pharma Solutions Pvt. Ltd.
(Formerly known as Genlink Pharma Investments Pvt. Ltd.)
CIN: U74110 MH 2016 PTC 280765

Statement of standalone financial results for the year ended March 31, 2017

		INR	
PARTICULARS		Previous year ended 31-March-17	Previous year ended 31-March-16
		Audited	
1	Income from Operations		
a	Net Sales / Income from Operations (net of excise duty)	1,750,000	-
b	Other Operating Income	-	-
	Total Income from Operations (net)	<u>1,750,000</u>	<u>-</u>
2	Expenses		
a	Cost of Materials consumed		
b	Purchase of stock-in-trade		
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade		
d	Employee benefit expenses		
e	Depreciation and amortization expense		
f	Other expenses	1,894,885	-
	Total Expenses	<u>1,894,885</u>	<u>-</u>
3	Profit/(Loss) from operations before other income, finance costs and exceptional items	<u>-144,885</u>	<u>-</u>
4	Other Income		
5	Profit/(Loss) from ordinary activities before finance cost and exceptional items (3-4)	<u>-144,885</u>	
6	Finance Cost	1,538,265	-
7	Profit/(Loss) from ordinary activities after finance cost but before exceptional items (5-6)	<u>-1,683,150</u>	<u>-</u>
8	Exceptional Items	-	-
9	Profit/(Loss) from ordinary activities before tax (7-8)	<u>-1,683,150</u>	<u>-</u>
10	Tax Expense	531,830	-
11	Net Profit/(Loss) from ordinary activities after tax (9-10)	<u>-2,214,980</u>	<u>-</u>
12	Extraordinary items (net of tax INR expense lacs)	-	-
13	Net Profit / Loss for the period (11-12)	<u>-2,214,980</u>	<u>-</u>
14	Paid up equity share capital (Face value of Rs.10 each)	100,000	-
15	Reserve excluding Revaluation Reserves as per Balance Sheet of previous accounting year	-2,214,980	-
16.i	Earnings Per Share (before extraordinary items) (of INR /- each) (not annualized):		
a	Basic	-244.99	-
b	Diluted	-244.99	-
16.ii	Earnings Per Share (after extraordinary items)		

	(of INR /- each) (not annualized):		
a	Basic	-244.99	-
b	Diluted	-244.99	-

Note

The financial year 2016-2017 is the first financial year of the Company.

For Shankarlal Jain & Associates LLP
Chartered Accountants
Registration No. 109901W/W100082
Officer
Sd/-
Satish Jain
Partner
Membership no. 048874
Mumbai
Date: 23.01.2018

For Genlink Pharma Solutions Private Limited
Anand Shah Susheel Koul Somnath Bomble
Director Managing Director Chief Financial
DIN 00597145 DIN 00925887
Navi Mumbai Navi Mumbai

Statement of Assets and Liabilities for Companies

Standalone Statement of Assets and Liabilities	INR	
	As at year end 31-March-17 Audited	As at (Previous year ended 31/03/2016
Particulars		
A EQUITY AND LIABILITIES		
1 Shareholders' funds		
(a) Share capital	100,000	-
(b) Reserves and surplus	-2,214,980	-
(c) Money received against share warrants	-	-
Sub-total - Shareholders' funds	-2,114,980	-
2. Share application money pending allotment		
3. Non-current liabilities		
(a) Long-term borrowings	250,000,000	-

(b) Deferred tax liabilities (net)	-	-
(c) Other long-term liabilities	-	-
(d) Long-term provisions	-	-
Sub-total - Non-current liabilities	250,000,000	-
4. Current liabilities		
(a) Short-term borrowings	-	-
(b) Trade payables	-	-
(c) Other current liabilities	1,817,241	-
(d) Short-term provisions	408,830	-
Sub-total - Current liabilities	2,226,071	-
TOTAL - EQUITY AND LIABILITIES	250,111,091	-
B ASSETS		
1. Non-current assets		
(a) Fixed assets	-	-
(b) Non-current investments	248,995,479	-
(c) Deferred tax assets (net)	-	-
(d) Long-term loans and advances	-	-
(e) Other non-current assets	-	-
Sub-total - Non-current assets	248,995,479	-
2 Current assets		
(a) Current investments	-	-
(b) Inventories	-	-
(c) Trade receivables	-	-
(d) Cash and cash equivalents	1,115,612	-
(e) Short-term loans and advances	-	-
(f) Other current assets	-	-
Sub-total - Current assets	1,115,612	-
TOTAL - ASSETS	250,111,091	-

Note

The financial year 2016-2017 is the first financial year of the Company.

For Shankarlal Jain & Associates LLP
Chartered Accountants
Registration No. 109901W/W100082
Officer
Sd/-
Satish Jain
Partner
Membership no. 048874
Mumbai
Date: 23.01.2018

For Genlink Pharma Solutions Private Limited
Anand Shah Susheel Koul Somnath Bomble
Director Managing Director Chief Financial

DIN 00597145 DIN 00925887
Navi Mumbai Navi Mumbai